KR101599556B1 - Ｒｓｖ-특이적 결합 분자 및 이의 제조 방법 - Google Patents

Ｒｓｖ-특이적 결합 분자 및 이의 제조 방법 Download PDF

Info

Publication number
KR101599556B1
KR101599556B1 KR1020097027481A KR20097027481A KR101599556B1 KR 101599556 B1 KR101599556 B1 KR 101599556B1 KR 1020097027481 A KR1020097027481 A KR 1020097027481A KR 20097027481 A KR20097027481 A KR 20097027481A KR 101599556 B1 KR101599556 B1 KR 101599556B1
Authority
KR
South Korea
Prior art keywords
antibody
sequence
ser
cells
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097027481A
Other languages
English (en)
Korean (ko)
Other versions
KR20100028592A (ko
Inventor
허겐 스피츠
팀 뷰몬트
에츠코 야스다
마르크 예로엔 콰켄보스
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20100028592A publication Critical patent/KR20100028592A/ko
Application granted granted Critical
Publication of KR101599556B1 publication Critical patent/KR101599556B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C07K16/11—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
KR1020097027481A 2007-06-01 2008-05-30 Ｒｓｖ-특이적 결합 분자 및 이의 제조 방법 Active KR101599556B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109472A EP1997830A1 (en) 2007-06-01 2007-06-01 RSV specific binding molecules and means for producing them
EP07109472.6 2007-06-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157005501A Division KR101652652B1 (ko) 2007-06-01 2008-05-30 Ｒｓｖ-특이적 결합 분자 및 이의 제조 방법

Publications (2)

Publication Number Publication Date
KR20100028592A KR20100028592A (ko) 2010-03-12
KR101599556B1 true KR101599556B1 (ko) 2016-03-04

Family

ID=38578633

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097027481A Active KR101599556B1 (ko) 2007-06-01 2008-05-30 Ｒｓｖ-특이적 결합 분자 및 이의 제조 방법
KR1020157005501A Active KR101652652B1 (ko) 2007-06-01 2008-05-30 Ｒｓｖ-특이적 결합 분자 및 이의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157005501A Active KR101652652B1 (ko) 2007-06-01 2008-05-30 Ｒｓｖ-특이적 결합 분자 및 이의 제조 방법

Country Status (22)

Country Link
US (5) US8562996B2 (cg-RX-API-DMAC7.html)
EP (3) EP1997830A1 (cg-RX-API-DMAC7.html)
JP (4) JP5450395B2 (cg-RX-API-DMAC7.html)
KR (2) KR101599556B1 (cg-RX-API-DMAC7.html)
CN (2) CN101778866B (cg-RX-API-DMAC7.html)
AU (1) AU2008257801B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0812878C1 (cg-RX-API-DMAC7.html)
CA (2) CA2950515A1 (cg-RX-API-DMAC7.html)
CY (1) CY1117767T1 (cg-RX-API-DMAC7.html)
DK (1) DK2170952T3 (cg-RX-API-DMAC7.html)
ES (1) ES2575129T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160632T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029225T2 (cg-RX-API-DMAC7.html)
IL (1) IL202288A (cg-RX-API-DMAC7.html)
MX (2) MX350375B (cg-RX-API-DMAC7.html)
NZ (3) NZ581512A (cg-RX-API-DMAC7.html)
PL (1) PL2170952T3 (cg-RX-API-DMAC7.html)
PT (1) PT2170952E (cg-RX-API-DMAC7.html)
RU (2) RU2527067C2 (cg-RX-API-DMAC7.html)
SI (1) SI2170952T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008147196A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908320B (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
BRPI0619579B8 (pt) 2005-12-09 2022-01-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Métodos para aumentar a expectativa de vida replicativa e/ou estabilidade de uma célula produtora de anticorpo, para expressar um gene de uma célula b codificando a cadeia pesada de ig e/ou cadeia leve de ig, para produzir linhagem de células b, para obter anticorpos, e, método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CA2704134A1 (en) * 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
EP2373689A1 (en) 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
AU2015200208B2 (en) * 2009-07-15 2016-10-20 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
JP5781508B2 (ja) * 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP5734988B2 (ja) * 2009-10-06 2015-06-17 メディミューン リミテド Ｒｓｖ特異的結合分子
CN104628850B (zh) * 2009-10-06 2020-07-28 医学免疫有限公司 Rsv-特异性结合分子
CN103097412B (zh) * 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
HUE033141T2 (en) * 2010-12-02 2017-11-28 Aimm Therapeutics Bv Instruments and methods for producing high affinity antibodies
AU2011343161B2 (en) 2010-12-17 2017-02-02 Neurimmune Holding Ag Human anti-SOD1 antibodies
BR112014010823B1 (pt) * 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
US9718876B2 (en) 2011-11-17 2017-08-01 Aimm Therapeutics B.V. RSV G protein specific antibodies
ES2657470T3 (es) * 2012-03-20 2018-03-05 Humabs Biomed S.A. Anticuerpos que neutralizan RSV, MPV y PVM y usos de los mismos
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
DK2950886T3 (da) * 2013-02-01 2020-03-23 Medimmune Llc Respiratorisk syncytialvirus-f-protein-epitoper
DK2970398T3 (da) 2013-03-13 2024-08-05 Us Health Præfusions-rsv-f-proteiner og anvendelse deraf
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
AU2014231357B2 (en) * 2013-03-15 2018-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epitope of RSV fusion protein and antibody identifying same
WO2015010792A1 (en) 2013-07-24 2015-01-29 Humabs Biomed Sa Antibodies that potently neutralize rsv and uses thereof
WO2015037992A1 (en) 2013-09-11 2015-03-19 Aimm Therapeutics B.V. Parechovirus specific antibodies
ES2729057T3 (es) 2013-12-17 2019-10-30 Aimm Therapeutics Bv Medios y métodos para contrarrestar trastornos mieloproliferativos o linfoproliferativos
PL3094353T3 (pl) 2014-01-15 2020-09-07 Medimmune, Llc Przeciwciała swoiste pod kątem RSV i ich funkcjonalne części
CA2938193C (en) 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US9340604B1 (en) * 2014-10-29 2016-05-17 Aridis Pharmaceuticals, Inc. Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
JP5996707B2 (ja) * 2015-04-15 2016-09-21 メディミューン リミテド Ｒｓｖ特異的結合分子
EP3313432A1 (en) 2015-06-18 2018-05-02 VIB vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
EP3124042A1 (en) 2015-07-28 2017-02-01 VIB, vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
BR112017027677A2 (en) 2015-06-24 2018-08-28 Aimm Therapeutics B.V. peptide, compound, nucleic acid molecule, vector, use of a peptide, antibody, immunogenic composition, kit, methods for determining if an individual has an antibody and for producing an immune cell and / or antibody, gene dispensing vehicle, and, host cell
KR102068915B1 (ko) 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
MY205060A (en) 2015-12-23 2024-09-30 Pfizer Rsv f protein mutants
CN109069611B (zh) 2016-03-29 2022-11-04 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
SG11201903287PA (en) 2016-10-21 2019-05-30 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
AU2017345786B2 (en) 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018075954A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR102809623B1 (ko) 2018-01-29 2025-05-16 머크 샤프 앤드 돔 엘엘씨 안정화된 rsv f 단백질 및 그의 용도
WO2019178521A1 (en) 2018-03-16 2019-09-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncitial virus infection
WO2019195291A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic respiratory syncytial virus polypeptides
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
EP3956351A1 (en) * 2019-04-18 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Biological and synthetic molecules inhibiting respiratory syncytial virus infection
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
KR20230018521A (ko) * 2020-06-02 2023-02-07 바텔리 메모리얼 인스티튜트 2019의 중증 급성 호흡기 증후군 코로나바이러스 2 (SARS-CoV-2) (COVID-19)를 스크리닝하기 위한 시스템 및 방법
KR102467943B1 (ko) * 2020-06-25 2022-11-16 재단법인 목암생명과학연구소 항-rsv 항체 및 이를 포함하는 약학적 조성물
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
KR20250054810A (ko) 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
CN120153078A (zh) 2022-10-27 2025-06-13 辉瑞大药厂 编码rsv-f的rna分子及含所述rna分子的疫苗
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
US12383614B2 (en) 2023-12-21 2025-08-12 Yikang Biotech (Suzhou) Co., Ltd. Mutants of respiratory syncytial virus fusion proteins
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069462A1 (en) * 1999-05-18 2000-11-23 Smithkline Beecham Corporation Human monoclonal antibody

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517304A (en) 1980-07-01 1985-05-14 National Research Development Corporation Production of viral antigens
DE3235924T1 (de) 1981-03-06 1983-05-05 Celltech Ltd., Slough, Berkshire Monoklonaler antikoerper
US4526934A (en) * 1982-03-19 1985-07-02 Bridgestone Tire Company Limited Branched styrene-butadiene copolymers and pneumatic tires using the same
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5340926A (en) 1983-03-25 1994-08-23 Celltech, Limited Process for the recovery of recombinantly produced protein from insoluble aggregate
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5332805A (en) 1984-02-03 1994-07-26 Celltech Limited Process for the recovery of recombinantly produced chymosin from insoluble aggregate
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4659563A (en) 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US4717766A (en) 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US5271927A (en) 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US5468606A (en) 1989-09-18 1995-11-21 Biostar, Inc. Devices for detection of an analyte based upon light interference
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB8719041D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
EP0396563B1 (en) 1987-12-23 1993-02-10 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
US5137804A (en) 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5354554A (en) 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
US6093872A (en) 1989-05-05 2000-07-25 Systemix, Inc. Extended human hematopoiesis in a heterologous host
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5518725A (en) 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
JP2571874B2 (ja) 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5279935A (en) 1990-03-01 1994-01-18 Becton, Dickinson And Company Method of immunossay including deactivation of endogenous alkaline phosphatase
DE69120890T2 (de) 1990-05-03 1997-02-20 Systemix Inc Menschliches lymph-gewebe in einem wirt mit angegriffenem immunsystem
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
ES2113428T3 (es) 1991-04-22 1998-05-01 Massachusetts Health Res Proceso de tamizado de muestras de plasma para determinar titulos de anticuerpos efectivos contra los virus respiratorios.
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
CA2044940A1 (en) 1991-06-10 1992-12-11 Inder M. Verma Transdominant negative proto-oncogene
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
US5240694A (en) 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5418136A (en) 1991-10-01 1995-05-23 Biostar, Inc. Devices for detection of an analyte based upon light interference
DK0614530T3 (da) 1991-11-15 1998-09-28 Cornell Res Foundation Inc Indirekte immunassay for dioxinlignende forbindelser
US20020102257A1 (en) 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
WO1993019197A1 (en) 1992-03-20 1993-09-30 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
GB9207479D0 (en) 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
ES2191016T3 (es) 1992-09-16 2003-09-01 Scripps Research Inst Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5424189A (en) 1993-03-05 1995-06-13 Kansas State University Research Foundation Bovine respiratory syncytial virus detection and primers
DK0705109T4 (da) 1993-05-25 2004-05-10 Wyeth Corp Adjuvanser til vacciner mod respiratorisk syncytialvirus
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
NZ269735A (en) 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
US5506209A (en) 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5538952A (en) 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5792456A (en) 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AU4755696A (en) 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
EP0853487B1 (en) 1995-09-18 2000-07-05 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
JP2000506165A (ja) 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
FR2758331B1 (fr) 1997-01-14 1999-03-05 Univ Bourgogne Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
EP0971696B1 (en) 1997-02-06 2010-06-09 Merck Sharp & Dohme Corp. Thimerosal-free preservatives for vaccines
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU760120B2 (en) 1997-12-01 2003-05-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
EP1180123B1 (en) 1999-05-27 2008-07-16 Government of the United States as represented by the Secretary, Department of Health and Human Services Immunoconjugates having high binding affinity
EP1265928B1 (en) 2000-01-27 2010-07-21 Medimmune, LLC Ultra high affinity rsv neutralizing antibodies
WO2002043660A2 (en) 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2001059142A1 (en) 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
CA2401652A1 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
AU2001241918A1 (en) 2000-03-02 2001-09-12 Med Immune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
EP1152199B1 (de) 2000-05-03 2005-07-27 IPV Inheidener Produktions- und Vertriebsgesellschaft mbH Thermobehälter
CA2409689A1 (en) 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies
AU2001261137B2 (en) 2000-05-03 2006-05-25 Medimmune, Llc Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
WO2001089562A1 (en) 2000-05-25 2001-11-29 Medimmune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
EP1343820A4 (en) * 2000-10-13 2005-09-14 Uab Research Foundation HUMANE SINGLE CHAIN ANTI EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20040096451A1 (en) 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
ATE484522T1 (de) 2001-04-24 2010-10-15 Bayer Corp Menschliche antikörper gegen timp-1
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8318487B2 (en) * 2001-12-18 2012-11-27 Cancer Research Technology Limited Materials and methods relating to the production and maintenance of cell lines
US6911321B2 (en) 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
WO2003102136A2 (en) * 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003251791B2 (en) 2002-07-03 2009-07-23 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1556403A4 (en) 2002-10-03 2006-06-28 Large Scale Biology Corp ENGINEERING MULTIMERIC PROTEINS
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
US7696334B1 (en) * 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
GB0306618D0 (en) 2003-03-22 2003-04-30 Univ Newcastle Antibody
US20050288491A1 (en) 2004-02-17 2005-12-29 Wilson David S Super-humanized antibodies against respiratory syncytial virus
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
US20060083741A1 (en) 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
JP2008518936A (ja) 2004-10-29 2008-06-05 メディミューン，インコーポレーテッド Ｒｓｖ感染症および関連状態を予防および治療する方法
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
AU2005307831A1 (en) 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
CN101128483B (zh) 2004-12-21 2015-06-03 阿斯利康公司 血管生成素-2的抗体及其应用
MX2007013217A (es) 2005-04-25 2008-03-11 Pfizer Anticuerpos contra miostatina.
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
BRPI0619579B8 (pt) * 2005-12-09 2022-01-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Métodos para aumentar a expectativa de vida replicativa e/ou estabilidade de uma célula produtora de anticorpo, para expressar um gene de uma célula b codificando a cadeia pesada de ig e/ou cadeia leve de ig, para produzir linhagem de células b, para obter anticorpos, e, método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110008329A1 (en) 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
KR20100087283A (ko) 2007-09-07 2010-08-04 심포젠 에이/에스 항­ｒｓｖ 항체의 재조합 제조 방법
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
JP5734988B2 (ja) 2009-10-06 2015-06-17 メディミューン リミテド Ｒｓｖ特異的結合分子
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
DK2950886T3 (da) 2013-02-01 2020-03-23 Medimmune Llc Respiratorisk syncytialvirus-f-protein-epitoper
PL3094353T3 (pl) 2014-01-15 2020-09-07 Medimmune, Llc Przeciwciała swoiste pod kątem RSV i ich funkcjonalne części

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069462A1 (en) * 1999-05-18 2000-11-23 Smithkline Beecham Corporation Human monoclonal antibody

Also Published As

Publication number Publication date
KR20150036796A (ko) 2015-04-07
CA2689290C (en) 2017-01-17
KR20100028592A (ko) 2010-03-12
HK1146073A1 (en) 2011-05-13
EP2578600A3 (en) 2013-07-31
NZ621824A (en) 2016-02-26
RU2014125126A (ru) 2015-09-20
IL202288A0 (en) 2010-06-16
AU2008257801A1 (en) 2008-12-04
WO2008147196A3 (en) 2009-02-05
ES2575129T3 (es) 2016-06-24
JP2014079251A (ja) 2014-05-08
JP2010528601A (ja) 2010-08-26
CA2950515A1 (en) 2008-12-04
IL202288A (en) 2016-10-31
HRP20160632T1 (hr) 2016-07-15
AU2008257801A8 (en) 2014-09-11
EP2170952B1 (en) 2016-03-09
US20180327484A1 (en) 2018-11-15
RU2009148886A (ru) 2011-07-20
US20140072575A1 (en) 2014-03-13
EP1997830A1 (en) 2008-12-03
BRPI0812878C1 (pt) 2021-05-25
US8562996B2 (en) 2013-10-22
EP2578600A2 (en) 2013-04-10
AU2008257801B8 (en) 2014-09-11
JP5450395B2 (ja) 2014-03-26
US20160244509A1 (en) 2016-08-25
HUE029225T2 (en) 2017-02-28
JP2017019836A (ja) 2017-01-26
RU2527067C2 (ru) 2014-08-27
MX350375B (es) 2017-09-05
US10730931B2 (en) 2020-08-04
CN101778866A (zh) 2010-07-14
KR101652652B1 (ko) 2016-08-30
NZ712667A (en) 2017-01-27
CN101778866B (zh) 2014-11-26
US20100239593A1 (en) 2010-09-23
MX2009012843A (es) 2010-04-21
WO2008147196A2 (en) 2008-12-04
PL2170952T3 (pl) 2016-10-31
US9321831B2 (en) 2016-04-26
BRPI0812878A2 (pt) 2015-03-31
SI2170952T1 (sl) 2016-08-31
CY1117767T1 (el) 2017-05-17
PT2170952E (pt) 2016-06-16
BRPI0812878B8 (pt) 2020-04-22
JP2018196380A (ja) 2018-12-13
CN104961825A (zh) 2015-10-07
NZ581512A (en) 2012-10-26
US10059757B2 (en) 2018-08-28
DK2170952T3 (en) 2016-06-20
US20140377279A9 (en) 2014-12-25
US20200325213A1 (en) 2020-10-15
RU2628095C2 (ru) 2017-08-14
BRPI0812878B1 (pt) 2020-01-21
EP2170952A2 (en) 2010-04-07
CA2689290A1 (en) 2008-12-04
AU2008257801B2 (en) 2014-08-14
ZA200908320B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
KR101599556B1 (ko) Ｒｓｖ-특이적 결합 분자 및 이의 제조 방법
KR101811886B1 (ko) 항―ｉｌ―17ｆ 항체 및 이의 사용 방법
JP2020508077A (ja) Ｃｄ２０抗原を標的とするキメラ抗原受容体の構築およびその遺伝子改変ｔ細胞の活性同定
RS50157B (sr) Neutrališuća visoko afinitivna humana monoklonalna antitela specifična za rsv f-protein i postupci za njihovu proizvodnju
CN111542342A (zh) 抗cd137抗体及其用途
KR20110128923A (ko) 인간 ｆａｓ에 대한 인간 항체 및 그의 용도
KR20110096591A (ko) Ｈｃｖ 감염의 치료적 처리 및 예방을 위한 의약으로서 항 ｈｃｖ 모노클로날 항체
AU2014262169B2 (en) Rsv-specific binding molecules and means for producing them
HK1146073B (en) Rsv-specific binding molecules and means for producing them

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091230

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130527

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140828

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150729

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20151129

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160225

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160225

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190129

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190129

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20200129

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20200129

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210127

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20220118

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230117

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240109

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20250210

Start annual number: 10

End annual number: 10